Efficacy News and Research

RSS

Sleep disorder treatment: an interview with Dr Seth Lederman, President and CEO of Tonix Pharmaceuticals

Sleep disorders are a large area. We are focused on one particular type of sleep disturbance called “non-restorative” sleep. People with this problem do sleep, but they don’t wake up feeling refreshed or feeling that their sleep has had the restorative effects of healthy sleep.

29 Aug 2012

Study finds decline in 30-day mortality of acute myocardial infarction with improved treatment

Improved treatment after acute myocardial infarction and less severe patient profile have reduced 30-day mortality over the past 15 years, according to research presented at ESC Congress 2012.

29 Aug 2012

Preventing falls in older people: an interview with Professor Lindy Clemson

We often think of tripping over a step edge or pathway obstruction but there can be a range of things that can contribute to a fall. One of the most common is that our ability to balance can be reduced. This means that we don’t recover from a trip and are at more of a risk of losing our balance.

29 Aug 2012

Top-line results from Rexahn’s Archexin Phase II study on metastatic pancreatic cancer

Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on developing multi-indication therapeutics in oncology and CNS, today announced top-line results from a Phase II clinical study of Archexin, its clinical-stage oncology drug candidate.

29 Aug 2012

Elixir Medical’s DESyne BD Novolimus Eluting Coronary Stent System receives CE Mark approval

Elixir Medical Corporation, a developer of product platforms that combine state-of-the-art medical devices with advanced pharmaceuticals, announced that it has received CE Mark approval for its DESyne BD Novolimus Eluting Coronary Stent System for the treatment of coronary artery disease.

29 Aug 2012

Altheus Therapeutics initiates enrollment in Zoenasa Phase 2 study for ulcerative colitis

Altheus Therapeutics announced today it has randomized its first patient in a comparator-controlled Phase 2 efficacy study of Zoenasa, a novel combination therapy for ulcerative colitis (UC).

29 Aug 2012

Herceptin® (trastuzumab) delivery methods: an interview with Dr Gustavo Ismael

Approximately 20% of all breast cancer patients have overexpression of HER2 (human epidermal growth factor receptor 2), resulting in a more aggressive phenotype, and a poor prognosis.

28 Aug 2012

Positive results from Spinifex’s EMA401 Phase 2 trial on postherpetic neuralgia

Spinifex Pharmaceuticals, an Australian pain drug development company, today announces positive headline results from the Phase 2 clinical trial of its lead product, EMA401, in postherpetic neuralgia (PHN), a painful condition that develops in some patients following herpes zoster (shingles) and where existing therapy does not relieve pain in all individuals.

28 Aug 2012

Nicotinamide may combat antibiotic-resistance staph infections

A new study suggests that nicotinamide, more commonly known as vitamin B3, may be able to combat some of the antibiotic-resistance staph infections that are increasingly common around the world, have killed thousands and can pose a significant threat to public health.

28 Aug 2012

Personalized antiplatelet treatment leads to better outcomes in patients undergoing PCI

Personalized antiplatelet treatment leads to better outcomes than standard antiplatelet treatment in patients undergoing coronary stent implantation, according to results from the MADONNA study presented at ESC Congress 2012.

28 Aug 2012

Morphotek commences MORAb-004 Phase II metastatic soft tissue sarcoma trial

Morphotek, Inc. announced today that it has commenced a multi-center, Phase II study evaluating the safety and efficacy of MORAb-004 when combined with gemcitabine and docetaxel in the treatment of metastatic soft tissue sarcoma.

28 Aug 2012

Leg compressions after stroke appear to trigger natural protective mechanisms that reduce damage

Successive, vigorous bouts of leg compressions following a stroke appear to trigger natural protective mechanisms that reduce damage, researchers report.

28 Aug 2012

Women with severe aortic stenosis less likely to die following TAVI

Women with severe aortic stenosis are 40% less likely to die after transcatheter aortic valve implantation (TAVI) than men, reveals the latest data from the largest study to date of gender differences in outcomes after TAVI.

27 Aug 2012

Mallinckrodt receives FDA approval for 32 mg tablet strength of EXALGO

The U.S. Food and Drug Administration (FDA) has notified Mallinckrodt, the pharmaceuticals business of Covidien, that it has approved a 32 mg tablet strength of EXALGO (hydromorphone HCI) Extended-Release Tablets (CII) for opioid-tolerant patients with moderate-to-severe chronic pain requiring continuous around-the-clock opioid analgesia for an extended period of time.

27 Aug 2012

Oral FluCide drug candidates effective in reducing lung viral load: NanoViricides

NanoViricides, Inc. announced today that anti-influenza drug candidates under its FluCide program, when given orally, were nearly as effective as when administered as IV injections in terms of reduction in lung viral load.

27 Aug 2012

FDA approves Mallinckrodt's EXALGO (32 mg) sNDA to manage opioid-related pain

Zalicus Inc., a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) filed by Mallinckrodt Inc., a subsidiary of Covidien plc, for the 32 mg dose strength of EXALGO (hydromorphone HCl) Extended-Release Tablets (CII), for the management of moderate to severe pain in opioid-tolerant patients requiring continuous, around-the-clock opioid analgesia for an extended period of time.

27 Aug 2012

IABP does not improve blood pressure symptoms in patients with cardiogenic shock

A balloon pump inserted in the aorta is currently the most widely used support device in the treatment of cardiogenic shock and, since its introduction in 1968, has been used in several million people.

27 Aug 2012

Debiopharm initiates enrollment in triptorelin phase III study for central precocious puberty

Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs and companion diagnostics, today announced that the first patient has been enrolled in an open-label phase III study to investigate the efficacy, safety, and pharmacokinetics of the sustained release triptorelin pamoate 22.5 mg 6-month-formulation in children with central precocious puberty (CPP), a rare disease.

27 Aug 2012

New data from Boehringer Ingelheim and Pfizer's tiotropium clinical studies on asthma, COPD

New data to be presented at the Annual Congress of the European Respiratory Society (ERS 2012), in Vienna, Austria, will shed light on the current and potential future role of tiotropium, the first once-daily long-acting inhaled anticholinergic for patients with Chronic Obstructive Pulmonary Disease (COPD).

27 Aug 2012

Study confirms electrical storm as potent risk factor for death and impaired quality of life

Electrical storm (ES) is a potent risk factor for mortality and morbidity, according to research presented today at the ESC Congress 2012 by Dr Federico Guerra from Italy. Data was also presented on which patients are prone to developing ES and how effective current treatments are.

27 Aug 2012

Efficacy News and Research

Sleep disorder treatment: an interview with Dr Seth Lederman, President and CEO of Tonix Pharmaceuticals

Study finds decline in 30-day mortality of acute myocardial infarction with improved treatment

Preventing falls in older people: an interview with Professor Lindy Clemson

Top-line results from Rexahn’s Archexin Phase II study on metastatic pancreatic cancer

Elixir Medical’s DESyne BD Novolimus Eluting Coronary Stent System receives CE Mark approval

Altheus Therapeutics initiates enrollment in Zoenasa Phase 2 study for ulcerative colitis

Herceptin® (trastuzumab) delivery methods: an interview with Dr Gustavo Ismael

Positive results from Spinifex’s EMA401 Phase 2 trial on postherpetic neuralgia

Nicotinamide may combat antibiotic-resistance staph infections

Personalized antiplatelet treatment leads to better outcomes in patients undergoing PCI

Morphotek commences MORAb-004 Phase II metastatic soft tissue sarcoma trial

Leg compressions after stroke appear to trigger natural protective mechanisms that reduce damage

Women with severe aortic stenosis less likely to die following TAVI

Mallinckrodt receives FDA approval for 32 mg tablet strength of EXALGO

Oral FluCide drug candidates effective in reducing lung viral load: NanoViricides

FDA approves Mallinckrodt's EXALGO (32 mg) sNDA to manage opioid-related pain

IABP does not improve blood pressure symptoms in patients with cardiogenic shock

Debiopharm initiates enrollment in triptorelin phase III study for central precocious puberty

New data from Boehringer Ingelheim and Pfizer's tiotropium clinical studies on asthma, COPD

Study confirms electrical storm as potent risk factor for death and impaired quality of life

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News